Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Cryan J et al. | FKBP, the binding protein for the immunosuppressive drug, FK-506, is not an inhibitor of protein kinase C activity. | 1991 | Biochem. Biophys. Res. Commun. | pmid:1719972 |
Ryu S and Yasunami Y | Prevention of immune rejection in rat islet allografts by continuous SC administration of FK 506 using a mini-osmotic pump. | 1991 | Transplant. Proc. | pmid:1703710 |
Karlsson H et al. | The immunosuppressive agent FK506 inhibits in vitro expression of membrane-bound and soluble interleukin-2 receptors on resting but not on activated human lymphocytes. | 1991 | Immunol. Lett. | pmid:1720417 |
Alejandro R et al. | Combined liver-islet allotransplantation in man under FK 506. | 1991 | Transplant. Proc. | pmid:1703712 |
FK-506 shows similar graft survival rate to cyclosporine but fewer side effects: Pitt transplant team. | 1991 | Nephrol News Issues | pmid:1720511 | |
Ito T et al. | The mechanism of tolerance induced by a perioperative injection of bone marrow cells and a brief course of FK 506. | 1991 | Transplant. Proc. | pmid:1703716 |
The discovery of FK-506 and U.S. development. | 1991 | Nephrol News Issues | pmid:1720512 | |
Zheng B et al. | Effects of the new and highly active immunosuppressant, rapamycin, on lymphoid tissues and cells in vivo. | 1991 | Transplant. Proc. | pmid:1703717 |
Christians U et al. | Interactions of FK 506 and cyclosporine metabolism. | 1991 | Transplant. Proc. | pmid:1721280 |
Wu YM et al. | Interaction between FK 506 and cyclosporine in dogs. | 1991 | Transplant. Proc. | pmid:1721281 |
Habucky K et al. | The pharmacodynamics of pentobarbital following FK 506 therapy. | 1991 | Transplant. Proc. | pmid:1721282 |
Andersson J et al. | The effects of FK 506 on cytokine production are dependent on the mode of cell activation. | 1991 | Transplant. Proc. | pmid:1721311 |
Wang SC et al. | FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line. | 1991 | Transplant. Proc. | pmid:1721312 |
Woo J et al. | Kinetics of early T-cell repopulation in the mouse following syngeneic bone marrow transplantation: FK 506 causes a maturational defect of CD4+ CD8- T cells. | 1991 | Transplant. Proc. | pmid:1721313 |
McCarthy SA et al. | Effects of FK 506 and cyclosporine on T-cell tolerance: inhibition of a "protective" mechanism that regulates activation-induced apoptosis in developing thymocytes. | 1991 | Transplant. Proc. | pmid:1721314 |
Mieles LA et al. | Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. | 1991 | Transplant. Proc. | pmid:1721344 |
Nakazato P et al. | Early experience with FK 506 induction immunosuppression--suggestion for using oral FK 506. | 1991 | Transplant. Proc. | pmid:1721345 |
Nakamura K et al. | The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. | 1991 | Transplant. Proc. | pmid:1721346 |
Jain AB et al. | Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. | 1991 | Transplant. Proc. | pmid:1721347 |
Gordon RD et al. | Liver transplantation under cyclosporine: a decade of experience. | 1991 | Transplant. Proc. | pmid:1703339 |
Todo S et al. | One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. | 1991 | Transplant. Proc. | pmid:1703340 |
Zeevi A et al. | Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection. | 1991 | Transplant. Proc. | pmid:1703341 |
van Hoek B et al. | Recurrence of ductopenic rejection in liver allografts after retransplantation for vanishing bile duct syndrome. | 1991 | Transplant. Proc. | pmid:1703343 |
Morris SM et al. | Disruption of renal function and gene expression by FK 506 and cyclosporine. | 1991 | Transplant. Proc. | pmid:1721375 |
Lieberman KV et al. | FK 506 is a direct glomeruloconstrictor, as determined by electrical resistance pulse sizing (ERPS). | 1991 | Transplant. Proc. | pmid:1721376 |
Ueda D et al. | Influence of FK 506 on renal blood flow. | 1991 | Transplant. Proc. | pmid:1721377 |
Perico N et al. | FK 506 does not affect the glomerular filtration rate and renal plasma flow in the rat. | 1991 | Transplant. Proc. | pmid:1721378 |
Pirsch JD et al. | Pulmonary infiltrates and eosinophilia in an FK 506 liver transplant recipient. | 1991 | Transplant. Proc. | pmid:1721406 |
Shinozuka H et al. | Effect of FK 506 on experimental liver carcinogenesis. | 1991 | Transplant. Proc. | pmid:1721407 |
Pelekanou V et al. | FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function. | 1991 | Transplant. Proc. | pmid:1721408 |
Tai J et al. | In vivo and in vitro effect of FK 506 on rat Leydig cell function. | 1991 | Transplant. Proc. | pmid:1721409 |
Goebl MG | The peptidyl-prolyl isomerase, FK506-binding protein, is most likely the 12 kd endogenous inhibitor 2 of protein kinase C. | 1991 | Cell | pmid:1706222 |
de Paulis A et al. | FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. | 1991 | J. Immunol. | pmid:1706398 |
Griffiths EJ and Halestrap AP | Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin. | 1991 | Biochem. J. | pmid:1706598 |
Jiang H et al. | Prolonged cardiac allograft survival in sensitized rats by low-dose FK 506 in combination with splenectomy. | 1991 | Transplant. Proc. | pmid:1721439 |
Sato K et al. | Comparative study of FK 506, cyclosporine, and triple regimen immunosuppression with FK 506, cyclosporine, and mizoribine. | 1991 | Transplant. Proc. | pmid:1721440 |
Katayama Y et al. | Immunosuppressive effects of FK 506 in rat lung transplantation. | 1991 | Transplant. Proc. | pmid:1721441 |
Yokomise H et al. | Immunosuppressive effects of FK 506 in canine lung transplantation. | 1991 | Transplant. Proc. | pmid:1721442 |
Hultsch T et al. | Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. | 1991 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1712484 |
Miyahara H et al. | Comparative studies of the effects of FK506 and cyclosporin A on passively transferred collagen-induced arthritis in rats. | 1991 | Clin. Immunol. Immunopathol. | pmid:1712688 |
McAlpine JB et al. | Revised NMR assignments for rapamycin. | 1991 | J. Antibiot. | pmid:1712766 |
Banerji SS et al. | The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. | 1991 | Mol. Cell. Biol. | pmid:1712901 |
Starzl TE et al. | [Clinical experience with FK 506]. | 1991 | Presse Med | pmid:1722311 |
Granelli-Piperno A and McHugh P | Characterization of a protein that regulates the DNA-binding activity of NF-AT, the nuclear factor of activated T cells. | 1991 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1722332 |
Nelson PA et al. | cDNA encoding murine FK506-binding protein (FKBP): nucleotide and deduced amino acid sequence. | 1991 | Gene | pmid:1722474 |
Chen MF et al. | The influence of FK-506 on the thymus and spleen in normal C3H/He mice: flow cytometric analysis of lymphocyte subpopulations. | 1991 | Immunol. Lett. | pmid:1722778 |
Fujino Y et al. | FK506 treatment of S-antigen induced uveitis in primates. | 1991 | Curr. Eye Res. | pmid:1717199 |
McWhinnie DL and Morris PJ | Combination drug therapies for immunosuppression in transplantation. | 1991 | Ann. Acad. Med. Singap. | pmid:1724724 |
Pourtier-Manzanedo A et al. | FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. | 1991 | Anticancer Drugs | pmid:1724925 |
Nakahama H et al. | Comparative effects of cyclosporine A and FK-506 on endothelin secretion by a cultured renal cell line, LLC-PK1. | 1991 | J. Cardiovasc. Pharmacol. | pmid:1725322 |